Join VolitionRX Limited (NYSE AMERICAN: VNRX) for an exciting webinar hosted by Edison Group! During the event, Volition’s multi-national epigenetics company will be discussing their Nu.Q® Vet commercial strategy and how it can help transform the veterinary industry. Don’t miss out on this exclusive opportunity to gain insight into the future of vet care!
Join us for an exciting webinar on Thursday, January 26th at 12 noon U.S. Eastern Time, featuring Dr. Tom Butera (Chief Executive Officer), Dr. Heather Wilson Robles (Chief Medical Officer), and Gael Forterre (Chief Commercial Officer) of Volition Veterinary Diagnostics Development LLC. Hear firsthand updates from all three executives on the latest developments in veterinary diagnostics and learn how you can stay ahead of the curve in this rapidly changing industry. Don’t miss out on this invaluable opportunity!
Join Soo Romanoff, Managing Director of Healthcare at Edison Group, for an exciting panel and Q&A event this week! Following the release of ‘Vetting the pet health opportunity’, an insightful report on Volition, this is a great opportunity to explore the potential of the pet health sector. Don’t miss out on this unique chance to gain valuable insights!
Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC, is proud to introduce the Nu.Q® Vet Cancer Test – a revolutionary and simple blood test for screening older or ‘at risk’ dogs. This cost effective and easy to use test provides pet owners with an accessible and affordable way to detect cancer in its early stages, offering a valuable opportunity for prevention and treatment.
We are thrilled to be entering a new and pivotal phase for Volition as we deploy our Nu.Q® technology in the companion animal healthcare industry and capitalize on the incredible potential of the mass market. This is an incredibly exciting time for the company, and we can’t wait to see the results.
Volition is revolutionizing the way we detect and manage life-altering diseases such as cancer. Through the development of simple, affordable blood tests, Volition is providing a more reliable, cost-effective means of diagnosing and monitoring illnesses in both humans and animals. This cutting-edge technology promises to drastically reduce the burden of these diseases and help improve patient outcomes.
Volition is revolutionizing the diagnosis and monitoring of life-altering diseases with its proprietary Nucleosomics™ platform. Through its subsidiaries, the company has developed simple, easy-to-use, cost-effective blood tests to detect a wide range of diseases, including some cancers and diseases associated with NETosis such as sepsis and COVID-19. By allowing for earlier diagnosis and monitoring, Volition’s tests have the potential to not only prolong the life of patients, but to also improve their quality of life significantly. The tests are based on the science of Nucleosomics™, which involves identifying and measuring nucleosomes in the bloodstream or other bodily fluids to indicate the presence of disease.
Volition’s research and development efforts are global, with a state-of-the-art innovation lab and offices in Belgium, the US, London, and Singapore. As a leader in the industry, the company is committed to pushing the boundaries of technology, creating groundbreaking solutions that shape the future.